Real-World Impact of Bimekizumab on Disease Activity in axial spondyloarthritis patients including the EARLY subpopulation (EXPEDITE)

First published: 30/04/2025

Last updated: 21/05/2025

Study Planned

Administrative details

EU PAS number

EUPAS1000000519

Study ID

1000000519

DARWIN EU® study

No

Study countries

- ☐ Austria
- ☐ Belgium
- ☐ European Union

- [ ] France
- [ ] Germany
- [ ] Greece
- [ ] Italy
- [ ] Netherlands
- [ ] Poland
- [ ] Spain
- [ ] Switzerland
- [ ] United Kingdom

Study status

Planned

Contact details

Study institution contact

UCB Cares UCBCares.global@ucb.com

Study contact

UCBCares.global@ucb.com

Primary lead investigator

UCB Cares

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 01/04/2025

Actual: 09/04/2025

Study start date
Planned: 30/05/2025

Date of final study report
Planned: 25/10/2027

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

UCB Biopharma SRL

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Other study registration identification numbers and links

Internal study ID: SPA002

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Study drug and medical condition

Name of medicine

BIMZELX

Study drug International non-proprietary name (INN) or common name

BIMEKIZUMAB

Anatomical Therapeutic Chemical (ATC) code

(L04AC21) bimekizumab

bimekizumab

Medical condition to be studied

Axial spondyloarthritis

Data management

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Yes

Check completeness

Yes

Check stability

Yes

Check logical consistency

Yes

Data characterisation

Data characterisation conducted

No